Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : FBN Associates: A Perfect Company -- Ignore unavailable to you. Want to Upgrade?

To: Don Pueblo who wrote (1388)	7/10/1998 7:35:00 PM
From: EL KABONG!!!	Read Replies (1) \| Respond to of 2117

TLC, What do you think of Petco's dramatic decline this afternoon? Good short term prospect for a little up action on Monday? Overreaction and oversold? KJC

To: Don Pueblo who wrote (1388)	7/14/1998 8:15:00 PM
From: TOPFUEL	Respond to of 2117

TEMPLE UNIVERSITY HAS THEIR OWN PATENT--1996 ON A VARIANT OF SANGUINES PRODUCT--SHOWS AS RECENTLY AS 1996 A MAJ0R UNIVERSITY HAS CONFIDENCE IN THIS TECH Non-Confidential Intellectual Property Summary Perfluorocarbon-Based Blood Substitute Reference Number: 175TS Background of the Invention A great deal of research and development is being devoted to the formulation of artificial blood substitutes. One of the approaches that have been used takes advantage of the remarkable oxygen and carbon dioxide delivery properties of perfluorocarbon (PFC) liquids. However, for PFCs to be useful as blood substitutes they must be dispersed into small particles which do not block blood vessels. Limitations of the Current Technology Dispersion of PFCs into small particles appears to have been accomplished so far only in the form of emulsions of various types. One such emulsion, marketed under the trade name Fluosol DA, must be stored at -40oC in order to overcome its inherent instability. The stability problem has been alleviated by the addition of stabilizers of various kinds. Great care must be taken to insure that the components of the stabilized emulsion are not harmful while in circulation (e.g., damage red blood cells) or by accumulating in various organs. Advantages Provided by the Invention The invention provides for the dispersion of PFCs within charged film microcapsules of a type developed at Temple University for intravenous delivery of pharmaceutical agents. For the purposes of this invention, microcapsules were made the size of red blood cells or slightly smaller, with narrow size distribution and with batch-to-batch variation within a few percent of mean diameter value. Capsular walls as thin as 0.1 micron permit high PFC loading efficiency. The microcapsules do not aggregate, are non-thrombogenic, and appear to escape capture by the reticuloendothelial system. Stability at room temperature is at least several months. The starting material may be sterilized and then used in totally enclosed batch or continuous flow manufacturing systems. The finished microcapsular formulations can also be sterilized prior to storage. Patent Status U.S. Patents 5,284,663 issued February 8, 1994 and 5,490,986 issued February 13, 1996. Next Previous Respond